Cargando…
Correction: The unintended mitochondrial uncoupling effects of the FDA-approved anti-helminth drug nitazoxanide mitigates experimental parkinsonism in mice
Autores principales: | Amireddy, Niharika, Puttapaka, Srinivas N., Vinnakota, Ravali L., Ravuri, Halley G., Thonda, Swaroop, Kalivendi, Shasi V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212635/ https://www.ncbi.nlm.nih.gov/pubmed/34144437 http://dx.doi.org/10.1016/j.jbc.2021.100864 |
Ejemplares similares
-
The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
por: Jasenosky, Luke D., et al.
Publicado: (2019) -
The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoprotein
por: Piacentini, Sara, et al.
Publicado: (2023) -
Target promiscuity and heterogeneous effects of tarantula venom peptides affecting Na(+) and K(+) ion channels.
por: Redaelli, Elisa, et al.
Publicado: (2010) -
The structure of the capsular polysaccharide of pneumococcal serotype 11A reveals a novel acetylglycerol that is the structural basis for 11A subtypes.
por: Zartler, Edward R., et al.
Publicado: (2011) -
Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts.
por: Sharma, Vandana, et al.
Publicado: (2011)